IGC Pharma, Inc. (IGC)

[noodle]

India Globalization Capital, Inc. (NYSE:IGC) has two lines of businesses, a legacy infrastructure business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer's patients. On December 26, 2017, the company announced that it will leverage its existing team of technology and healthcare experts to develop methods utilizing blockchain in areas such as product identification assurance (PIA). As previously reported, IGC has a two-part strategy for commercializing its lead product, Hyalolex. It is anticipated that in 2018, subject to adequate funding, to move the Alzheimer's formulation through FDA registered pre-clinical and clinical trials. Independent of the FDA process, IGC expects to license its formulation technology for distribution as a Complimentary and Alternative Medicine (CAM) through licensed medical cannabis dispensaries in key markets of the U.S.